Research demonstrates the potential of thiazole amide derivatives targeting GPR52 for schizophrenia treatment, suggesting new therapeutic avenues.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: